middle.news
Prescient Therapeutics Accelerates PTX-100 Trial Enrolment and Appoints New CMO
12:36pm on Monday 27th of July, 2026 AEST
•
Healthcare
Read Story
Prescient Therapeutics Accelerates PTX-100 Trial Enrolment and Appoints New CMO
12:36pm on Monday 27th of July, 2026 AEST
Key Points
PTX-100 Phase 2a enrolment reaches 28 patients
Cash reserves stand at $9.03 million at June 30
Dr Rosalind Wilson appointed Chief Medical Officer
Global clinical sites in Australia, US, Italy, with France planned
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE